Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer

Oncology Letters

Volumn 3, Issue 1, 2012, Pages 163-171

  Rhodes, Lyndsay V ^a   Tilghman, Syreeta L ^d   Boue, Stephen M ^c   Wang, Shuchun ^a   Khalili, Hafez ^a   Muir, Shannon E ^a   Bratton, Melyssa R ^b   Zhang, Qiang ^e   Wang, Guangdi ^e,f   Burow, Matthew E ^a,b   Collins Burow, Bridgette M ^a  

^a Section of Hematology and Medical Oncology   (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c U S DEPARTMENT OF AGRICULTURE   (United States)

^d College of Pharmacy   (United States)

^e RCMI Cancer Research Center   (United States)

^f XAVIER UNIVERSITY OF LOUISIANA   (United States)

Author keywords

Glyceollins; MicroRNA; Triple negative breast cancer; Tumorigenesis

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLYCEOLLIN; ISOFLAVONOID; MICRORNA; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOGENESIS; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

EID: 84855230116     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.460     Document Type: Article

References (79)

1. Reis-Filho JS and Tutt AN: Triple negative tumours: a critical review. Histopathology 52: 108-118, 2008.
2. Hu Z, Fan C, Oh DS, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96, 2006.
3. Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progeste-rone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a popu-lation-based study from the California cancer registry. Cancer 109: 1721-1728, 2007.
4. Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434, 2007.
5. Gail MH, Anderson WF, Garcia-Closas M and Sherman ME: Absolute risk models for subtypes of breast cancer. J Natl Cancer Inst 99: 1657-1659, 2007.
6. Reis-Filho JS, Westbury C and Pierga JY: The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol 59: 225-231, 2006.
7. Messina M: A brief historical overview of the past two decades of soy and isoflavone research. J Nutr 140: 1350S-1354S, 2010
8. Murkies AL, Wilcox G and Davis SR: Clinical review 92: Phytoestrogens. J Clin Endocrinol Metab 83: 297-303, 1998.
9. Tham DM, Gardner CD and Haskell WL: Clinical review 97: Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 83: 2223-2235, 1998.
10. Humfrey CD: Phytoestrogens and human health effects: weighing up the current evidence. Nat Toxins 6: 51-59, 1998.
11. Collins-Burow BM, Burow ME, Duong BN and McLachlan JA: Estrogenic and antiestrogenic activities of flavonoid phytochemicals through estrogen receptor binding-dependent and -independent mechanisms. Nutr Cancer 38: 229-244, 2000.
12. Collins BM, McLachlan JA and Arnold SF: The estrogenic and antiestrogenic activities of phytochemicals with the human estrogen receptor expressed in yeast. Steroids 62: 365-372, 1997.
13. Fournier DB, Erdman JW Jr and Gordon GB: Soy, its components, and cancer prevention: a review of the in vitro, animal, and human data. Cancer Epidemiol Biomarkers Prev 7: 1055-1065, 1998.
14. Barnes S: The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res Treat 46: 169-179, 1997.
15. Lamartiniere CA, Zhang JX and Cotroneo MS: Genistein studies in rats: potential for breast cancer prevention and reproductive and developmental toxicity. Am J Clin Nutr 68: 1400S-1405S, 1998.
16. Diel P, Smolnikar K, Schulz T, Laudenbach-Leschowski U, Michna H and Vollmer G: Phytoestrogens and carcinogenesis-differential effects of genistein in experimental models of normal and malignant rat endometrium. Hum Reprod 16: 997-1006, 2001.
17. Boue SM, Carter CH, Ehrlich KC and Cleveland TE: Induction of the soybean phytoalexins coumestrol and glyceollin by Aspergillus. J Agric Food Chem 48: 2167-2172, 2000.
18. Bhattacharyya M, Ward, EWB: Resistance, susceptibility and accumulation of glyceollins I-III in soybean organs inoculated with Phytophthora megasperma f. sp. Glycinea. Physiol and Mol Plant Pathol 29: 227-237, 1986.
19. Boue SM, Wiese TE, Nehls S, Burow ME, Elliott S, Carter-Wientjes CH, Shih BY, McLachlan JA and Cleveland TE: Evaluation of the estrogenic effects of legume extracts containing phytoestrogens. J Agric Food Chem 51: 2193-2199, 2003.
20. Graham TL and Graham MY: Glyceollin elicitors induce major but distinctly different shifts in isoflavonoid metabolism in proximal and distal soybean cell populations. Mol Plant Microbe Interact 4: 60-68, 1991.
21. Burow ME, Boue SM, Collins-Burow BM, et al: Phytochemical glyceollins, isolated from soy, mediate antihormonal effects through estrogen receptor alpha and beta. J Clin Endocrinol Metab 86: 1750-1758, 2001.
22. Salvo VA, Boue SM, Fonseca JP, et al: Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clin Cancer Res 12: 7159-7164, 2006.
23. Rhodes LV, Muir SE, Elliott S, et al: Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat 121: 293-300, 2010.
24. Burow ME, Tang Y, Collins-Burow BM, et al: Effects of environmental estrogens on tumor necrosis factor alpha-mediated apoptosis in MCF-7 cells. Carcinogenesis 20: 2057-2061, 1999.
25. Gao X, Gulari E and Zhou X: In situ synthesis of oligonucleotide microarrays. Biopolymers 73: 579-596, 2004.
26. Zhu Q, Hong A, Sheng N, et al: MicroParaflo biochip for nucleic acid and protein analysis. Methods Mol Biol 382: 287-312, 2007.
27. Bolstad BM, Irizarry RA, Astrand M and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193, 2003.
28. Farazi TA, Spitzer JI, Morozov P and Tuschl T: MiRNAs in human cancer. J Pathol 223: 102-115, 2011.
29. Winter J and Diederichs S: MicroRNA biogenesis and cancer. Methods Mol Biol 676: 3-22, 2011.
30. Allen KE and Weiss GJ: Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther 9: 3126-3136, 2011.
31. Gandellini P, Profumo V, Folini M and Zaffaroni N: MicroRNAs as new therapeutic targets and tools in cancer. Expert Opin Ther Targets 15: 265-279, 2011.
32. Nana-Sinkam SP and Croce CM: MicroRNA dysregulation in cancer: opportunities for the development of microRNA-based drugs. IDrugs 13: 843-846, 2011.
33. Ma L and Weinberg RA: MicroRNAs in malignant progression. Cell Cycle 7: 570-572, 2008.
34. O'Day E and Lal A: MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 12: 201, 2011.
35. Gregory PA, Bracken CP, Bert AG and Goodall GJ: MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 7: 3112-3118, 2008.
36. Korpal M and Kang Y: The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 5: 115-119, 2008.
37. Chen J, Wang L, Matyunina LV, Hill CG and McDonald JF: Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol 121: 200-205, 2011.
38. Tryndyak VP, Beland FA and Pogribny IP: E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 126: 2575-2583, 2011.
39. Ota D, Mimori K, Yokobori T, et al: Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients. Int J Oncol 38: 955-962, 2011.
40. Patel JB, Appaiah HN, Burnett RM, et al: Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene 30: 1290-1301, 2011.
41. Li J, Liang S, Yu H, Zhang J, Ma D and Lu X: An inhibitory effect of miR-22 on cell migration and invasion in ovarian cancer. Gynecol Oncol 119: 543-548, 2011.
42. Li J, Liang SH and Lu X: Potential role of ezrin and its related microRNA in ovarian cancer invasion and metastasis. Zhonghua Fu Chan Ke Za Zhi 45: 787-792, 2011.
43. Wu N, Zhao X, Liu M, et al: Role of microRNA-26b in glioma development and its mediated regulation on EphA2. PLoS One 6: e16264, 2011.
44. Liu XX, Li XJ, Zhang B, et al: MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11. FEBS Lett 585: 1363-1367, 2011.
45. Martinez I, Cazalla D, Almstead LL, Steitz JA and DiMaio D: MiR-29 and miR-30 regulate B-Myb expression during cellular senescence. Proc Natl Acad Sci USA 108: 522-527, 2011.
46. Villarreal G Jr, Oh DJ, Kang MH and Rhee DJ: Coordinated Regulation of Extracellular Matrix Synthesis by the MicroRNA-29 Family in the Trabecular Meshwork. Invest Ophthalmol Vis Sci 52: 3391-3397, 2011.
47. Maurer B, Stanczyk J, Jungel A, et al: MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 62: 1733-1743, 2011.
48. Li Z, Hassan MQ, Jafferji M, et al: Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem 284: 15676-15684, 2009.
49. Ott CE, Grunhagen J, Jager M, et al: MicroRNAs differentially expressed in postnatal aortic development downregulate elastin via 3' UTR and coding-sequence binding sites. PLoS One 6: e16250, 2011.
50. Mott JL, Kobayashi S, Bronk SF and Gores GJ: Mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 26: 6133-6140, 2007.
51. Park SY, Lee JH, Ha M, Nam JW and Kim VN: MiR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 16: 23-29, 2009.
52. Hashimoto Y, Akiyama Y, Otsubo T, Shimada S and Yuasa Y: Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis. Carcinogenesis 31: 777-784, 2011.
53. Li D, Zhao Y, Liu C, et al: Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res 7: 1722-1730, 2011.
54. Wang X, Wang J, Ma H, Zhang J and Zhou X: Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. Med Oncol: March 10, 2011 (E-pub ahead of print).
55. Sekiya Y, Ogawa T, Iizuka M, Yoshizato K, Ikeda K and Kawada N: Down-regulation of cyclin E1 expression by microRNA-195 accounts for interferon-beta-induced inhibition of hepatic stellate cell proliferation. J Cell Physiol 226: 2535-2542, 2011.
56. Liu L, Chen L, Xu Y, Li R and Du X: MicroRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun 400: 236-240, 2011.
57. Tili E, Michaille JJ, Adair B, et al: Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis 31: 1561-1566, 2011.
58. Pan J, Hu H, Zhou Z, et al: Tumor-suppressive mir-663 gene induces mitotic catastrophe growth arrest in human gastric cancer cells. Oncol Rep 24: 105-112, 2011.
59. Zhang X, Yu H, Lou JR, et al: MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem 286: 1429-1435, 2011.
60. Ory B, Ramsey MR, Wilson C, et al: A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest 121: 809-820, 2011.
61. Du L, Schageman JJ, Subauste MC, et al: MiR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res 7: 1234-1243, 2009.
62. Arndt GM, Dossey L, Cullen LM, et al: Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 9: 374, 2009.
63. Li Q, Wang G, Shan JL, et al: MicroRNA-224 is upregulated in HepG2 cells and involved in cellular migration and invasion. J Gastroenterol Hepatol 25: 164-171, 2011.
64. Mees ST, Mardin WA, Sielker S, et al: Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol 16: 2339-2350, 2009.
65. Wingett DG, Vestal RE, Forcier K, Hadjokas N and Nielson CP: CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res Treat 50: 27-36, 1998.
66. Castilla MA, Moreno-Bueno G, Romero-Perez L, et al: Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol 223: 72-80, 2011.
67. Bonci D: MicroRNA-21 as therapeutic target in cancer and cardiovascular disease. Recent Pat Cardiovasc Drug Discov 5: 156-161, 2011.
68. Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA and Stathopoulos EN: MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 10: 507-517, 2011.
69. Mei M, Ren Y, Zhou X, et al: Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol Cancer Res Treat 9: 77-86, 2011.
70. Gong C, Yao Y, Wang Y, et al: Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 286: 19127-19137, 2011.
71. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133: 647-658, 2007.
72. Qi L, Bart J, Tan LP, et al: Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer 9: 163, 2009.
73. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A and Lund AH: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 283: 1026-1033, 2008.
74. Song B, Wang C, Liu J, et al: MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res 29: 29, 2010.
75. Zhu S, Si ML, Wu H and Mo YY: MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282: 14328-14336, 2007.
76. Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo YY: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18: 350-359, 2008.
77. Russell RL, Pedersen AN, Kantor J, et al: Relationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines. Br J Cancer 78: 710-717, 1998.
78. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW and Waltham M: Vimentin and epithelial-mesenchymal transition in human breast cancer - observations in vitro and in vivo. Cells Tissues Organs 185: 191-203, 2007.
79. Joglekar MV, Patil D, Joglekar VM, et al: The miR-30 family microRNAs confer epithelial phenotype to human pancreatic cells. Islets 1: 137-147, 2009.